-25.8%
QBTS vs MRNA
-24.9%
-0.9%
-96.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.9% | +1.3% | -6.2% | -5.1% |
| 7D | -25.7% | -13.8% | -11.9% | -24.3% |
| 30D | -37.9% | -17.7% | -20.3% | -36.4% |
| 3M | -62.2% | +14.3% | -76.5% | -63.0% |
| 6M | -59.8% | +336.0% | -395.8% | -71.3% |
| YTD | -72.0% | +575.9% | -648.0% | -82.4% |
| 1Y | -68.8% | +724.4% | -793.2% | -81.3% |
| 3Y | +751.0% | +160.8% | +590.2% | +505.3% |
| 5Y | -25.8% | -24.4% | -1.4% | -44.2% |
| All | -25.8% | -24.9% | -0.9% | -44.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling